Focal liver lesions: Whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose

Nural M. S., Gokce E., Danacı M., Bayrak İ. K., Diren H. B.

EUROPEAN JOURNAL OF RADIOLOGY, cilt.66, sa.1, ss.65-74, 2008 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 66 Sayı: 1
  • Basım Tarihi: 2008
  • Doi Numarası: 10.1016/j.ejrad.2007.04.022
  • Dergi Adı: EUROPEAN JOURNAL OF RADIOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.65-74
  • Anahtar Kelimeler: gadobenate dimeglumine, focal liver lesions, magnetic resonance imaging, GD-BOPTA, NODULAR HYPERPLASIA, CONTRAST AGENTS, IMAGES
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

Objective: Gadobenate dimeglumine (Gd-BOPTA) is a liver-specific contrast agent also showing a distribution in the extracellular compartment which is recommended to be used at standard dose (0.05 mmol/kg) in magnetic resonance imaging (MRI) of liver lesions. However, its use at 0.1 mmol/kg is gradually increasing in recent clinical practice. Which dose should we use in routine MRI of liver lesions from now on? This study investigated the efficacy of Gd-BOPTA at a standard dose versus 0.1 mmol/kg dose in demonstrating diagnostic data in MRI of focal liver lesions.